VivoSim Labs Signs Seven-Figure Agreement with a Top-10

New Post Public Reply Private Reply Replies (0) Message Board
louied91
63
VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027

https://www.globenewswire.com/news-release/20...-2027.html

SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3D human cellular models for preclinical safety and efficacy testing, today announced a seven-figure agreement with a top-10 global pharmaceutical company (the “Customer”) for NAMkind™ testing services. With this agreement, the Company expects fiscal 2027 revenue to exceed the guidance of 500%+ growth it issued on July 15, 2026.

The agreement covers NAMkind™ liver and intestinal toxicology testing, with work already underway. Revenue under the agreement is expected to be recognized in VivoSim’s fiscal Q3 and Q4, ending Dec. 31 and March 31, respectively.
After this program, VivoSim anticipates that NAMkind™ testing will become part of the Customer's regular flow of ongoing preclinical work.
The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 12, shows growth in both its liver toxicology and intestinal toxicology businesses.
Growth came from both large pharma and smaller customers. Other current and future customers are also expected to move toward full integration of NAMkind™ testing into their workflows

How a Large Customer Adopts a New Test

A large pharmaceutical company (>$10B in annual revenue) does not quickly change how it tests drug candidates and requires extensive scientific due diligence to consider this kind of agreement. It then runs a new model on compounds whose clinical outcomes it already knows, compares the results with what its animal studies showed, and only then commits live program work. The agreement announced today covers that program work. Once it is complete, the Company anticipates that the Customer's compounds will come to VivoSim as the Customer's programs reach the relevant decision point, rather than as one-off studies.

“In July we told shareholders revenue would grow more than 500% this fiscal year. The quarterly report we filed last week shows both toxicology businesses growing, and this agreement on its own is expected to take us past that number,” said Keith Murphy, Executive Chairman of VivoSim Labs. “What matters more is what comes after it. A top-10 company has gone from evaluating our human liver and intestine models to paying for program work, and we expect its regular testing to follow. Other large customers are moving the same way.”

Since the Quarter Closed

On October 21, VivoSim added efficacy testing on disease models built from the liver and intestinal cells of patient donors, with pharmacodynamic and target biomarker profiling. On November 3, it entered a collaboration with Chemveda Life Sciences, which makes AI-designed compounds that VivoSim will then test in its human tissue models, with first programs expected to begin this quarter. This week, the Company's scientists are presenting new data demonstrating the practical impact on clinical derisking for clients of its multiparametric approach at the American College of Toxicology 47th Annual Meeting in San Antonio, Texas. The Company’s leadership is also meeting with current and prospective partners at the conference.

What Customers Are Buying

NAMkind™ liver and intestine models are built from primary human cells and dosed repeatedly over weeks. Across a clinical dataset of 92 small-molecule compounds, the NAMkind™ Liver model predicted drug-induced liver injury with 91% accuracy, 90% sensitivity and 95% specificity, whereas animal models and traditional methods typically detect 50% to 65% of true liver toxicants. Data presented at EUROTOX 2026 in September added further results in antibody-drug conjugates. Also in September, the U.S. Food and Drug Administration issued a direct final rule clarifying that non-animal methods may be used, where appropriate, to test the safety of drugs and biologics.

“Both toxicology service lines grew in the September quarter, with orders from large pharmaceutical companies and from smaller biotechs,” said Tony Lialin, Chief Commercial Officer of VivoSim Labs. “A large customer comes in through an evaluation, then a paid program, then its standing workflow. This Customer is at the second step, and we have others at the first.”
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 65

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 51

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 47

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
News Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles